A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors

Trial Profile

A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs SGT 53 (Primary) ; Cyclophosphamide; Topotecan
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SynerGene Therapeutics
  • Most Recent Events

    • 15 May 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 15 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 04 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top